Previous 10 | Next 10 |
Burning Rock Biotech (NASDAQ: BNR ) announces a strategic partnership with CStone Pharmaceuticals ( OTCPK:CSPHF ) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines (NASDAQ: BPMC...
Sorrento Provides Positive Update for COVIDTRAP Sorrento Therapeutics Inc. ( SRNE ) announced completing the preclinical batch of COVIDTRAP protein. The company reported that it has obtained positive results from preclinical testing of the drug candidate STI-4398. Sorrento plans to devel...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
Blueprint Medicines (NASDAQ: BPMC ) announces updated data from part 1 of a Phase 2 clinical trial, PIONEER , evaluating Ayvakit (avapritinib) in patients with indolent (slow-growing) systemic mastocytosis. The results were virtually presented at the European Academy of Allergy and Clinic...
CAMBRIDGE, Mass. , June 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated clinical data from part 1 of the PIONEER trial showing robust...
CAMBRIDGE, Mass. , June 3, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on June 1, 2020 , the Compensation Committee of...
CAMBRIDGE, Mass. , May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in pat...
CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming inves...
CAMBRIDGE, Mass. , May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webc...
Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...